Long-term safety of photobiomodulation therapy for oral mucositis in hematopoietic cell transplantation patients: a 15-year retrospective study

Abstract

Photobiomodulation therapy (PBMT) has demonstrated e cacy in the prevention and treatment of oral mucositis (OM) in hematopoietic cell transplantation (HCT). However, based on the cell stimulation properties, its long-term safety has been questioned, mainly in relation to risk for secondary malignancies in the oral cavity. The aim of this study was to investigate if different PBMT protocols for OM control have association with immediate and late adverse effects in HCT patients. Data on autologous and allogeneic transplantation, conditioning regimen, PBMT protocols, and OM severity were retrospectively collected from medical and dental records. Presence of secondary malignancies in the oral cavity was surveyed during a 15-year follow-up. Impact of OM on overall survival was also analyzed. Different PBMT protocols for prevention and treatment of OM were recorded over the years. Severe OM (grades 3 and 4) was infrequently observed. When present we observed a signi cant decrease of the overall survival. No immediate adverse effect and secondary malignancy was associated to PBMT. In conclusion, the PBMT protocols used in the study were considered safe. The low frequency of severe OM observed encourages the implementation of this technique, with a special emphasis on the dosimetry adjustments focused on the HCT context.

The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial)

“…In addition, various clinical trials investigated the safety of PBM in patients with cancer. Most of them focused on the use of PBM for the management of oral mucositis during cancer therapy and observed no altered treatment outcomes [ 40 – 45 ].…”

Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

“…PBM uses non-thermal light for therapeutic purposes via the modulation of cellular activities and responses. The therapeutic property of PBM was first discovered in the 1960s by Dr. Endre Mester [ 68 ], with clinical applications significantly increasing in recent years due to its broad range of biological activities and decades-long safety records [ 69 , 70 , 71 ]. Generally, PBM is performed with a low-powered laser or light-emitting diodes (LED).…”

Oral care and photobiomodulation protocol for the prevention of traumatic injuries and lip necrosis in critically ill patients with COVID-19: an observational study

“…The number of points varied, depending on the size of the area of the injury, with the goal of covering the entire lesion and the immediate surrounded tissues. The PBM application protocol was adapted from Bezinelli et al [18] with the objective to control inflammation and stimulate tissue healing, preventing the formation of tissue necrosis. It is important to state that the validation and calibration of the equipment are done by the manufacturer, once a year.…”